# Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Canonical URL: https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-upcoming-virtual-fireside-chat-hosted-by-titan-par-a0681614
Ticker: GNLX
Company: Genelux
Source: Genelux
Published: 2026-01-12 21:00 EST
## Summary

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...

## Article Body
Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT.

A live webcast of the fireside chat can be found here and on the investor relations section of the Company’s website at https://investors.genelux.com/ . Following the live webcast, an archived replay will be available on the Company’s website.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

Investor Contact

Austin Murtagh Precision AQ austin.murtagh@precisionaq.com

Media Contact

Ashley Murphy Precision AQ ashley.murphy@precisionaq.com

Source: Genelux Corporation
## Recent Company News
- 2026-06-30 12:00 EST — [Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer](https://biopharmsignal.com/news/GNLX/genelux-announces-publication-of-translational-analysis-supporting-immune-activa-f94dc658) — Source: Genelux
- 2026-05-07 20:15 EST — [Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates](https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-first-quarter-financial-results-and-provides-busines-4da315c4) — Source: Genelux
- 2026-03-19 20:15 EST — [Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2025-financial-results--c85e79a0) — Source: Genelux
- 2026-02-18 13:00 EST — [Genelux Corporation to Participate in Upcoming Conferences](https://biopharmsignal.com/news/GNLX/genelux-corporation-to-participate-in-upcoming-conferences-2aef90ae) — Source: Genelux
- 2026-01-12 21:00 EST — [Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners](https://biopharmsignal.com/news/GNLX/genelux-corporation-announces-upcoming-virtual-fireside-chat-hosted-by-titan-par-a0681614) — Source: Genelux
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)